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SUMMARY
Transfection of a Kaposi’s sarcoma (KS) herpesvirus (KSHV) Bacterial Artificial Chromosome
(KSHVBac36) into mouse bone marrow endothelial-lineage cells generates a cell (mECK36) that forms
KS-like tumors in mice. mECK36 expressed most KSHV genes and were angiogenic, but they didn’t
form colonies in soft agar. In nude mice, mECK36 formed KSHV-harboring vascularized spindle
cell sarcomas that were LANA+/podoplanin+, overexpressed VEGF and Angiopoietin ligands and
receptors, and displayed KSHV and host transcriptomes reminiscent of KS. mECK36 that lost the
KSHV episome reverted to nontumorigenicity. siRNA suppression of KSHV vGPCR, an angiogenic
gene upregulated in mECK36 tumors, inhibited angiogenicity and tumorigenicity. These results
show that KSHV malignancy is in vivo growth restricted and reversible, defining mECK36 as a biolog-
ically sensitive animal model of KSHV-dependent KS.INTRODUCTION
Human herpesvirus-8 or Kaposi’s sarcoma-associated
herpesvirus (KSHV) is associated with three AIDS-related
malignancies: Kaposi’s sarcoma (KS) (Boshoff and Weiss,
1998; Chang et al., 1994; Ganem, 2006), Multicentric Cas-
tlemans disease (Dupin et al., 1999), and primary effusionlymphoma (Cesarman et al., 1995). In HIV-infected individ-
uals, predominantly in the male homosexual population,
the incidence of KS dramatically increases and can man-
ifest as an advanced disseminated cancer with increased
morbidity and mortality (Gallo, 1998). The development of
pathogenesis-based therapies is important for improving
current KS treatments (Pantanowitz and Dezube, 2004).SIGNIFICANCE
Kaposi’s sarcoma (KS) herpesvirus (KSHV) is the etiologic agent of KS, an angiogenic spindle cell sarcoma asso-
ciated with AIDS. The mechanisms driving KSHV carcinogenesis could be uncovered through reproduction of KS
by KSHV infection of normal cells. Our results defining this cell and animal model of KS show that KSHV-induced
neoplasia is reversible, KSHV dependent, and in vivo restricted. Upregulation of KSHV genes, such as the proan-
giogenic vGPCR, under in vivo growth conditions provides a selective advantage to KSHV-harboring cells and
leads to episome maintenance and tumorigenesis. Thus, mECK36 tumors are phenotypic, molecular, and viral sur-
rogates of KS that are suitable for analyzing the role of viral and host genes in KS pathogenesis, and for preclinical
testing of anti-KS drugs.Cancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc. 245
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Animal Model of KSHV-Induced Kaposi’s SarcomaKS presents itself as multifocal lesions in the skin, lungs,
and gastrointestinal tract (Safai et al., 1985). It is charac-
terized by intense VEGF-mediated angiogenesis, spindle
cell proliferation, and erythrocyte extravasation (Gallo,
1998; Safai et al., 1985). There are many key unanswered
issues in KS pathogenesis that are matters of controversy
and intense research: (1) the neoplastic nature of KS, (2)
the identity of the normal cell type that upon infection
with KSHV becomes a malignant KS spindle cell, (3) the
connection between KSHV gene expression and the KS
phenotype, and (4) the relationship between KSHV biology
and other KS cofactors, such as immunosuppression, HIV
infection, and sexual transmission. Primary to answering
these questions is the development of an experimental
model of KSHV infection that reproduces the main patho-
genic phenotypes of KS in vitro and in animals.
While spindle cells are generally considered the tumor
cell in KS lesions, their origin and true malignant nature
are controversial, because they lack many features of neo-
plastic cells such as aneuploidy, tumorigenicity (Gallo,
1998), or clonality (Gill et al., 1998). KS spindle cells ex-
press phenotypic markers that belong to many cell line-
ages, including endothelium, smooth muscle cells, mac-
rophages, and hematopoietic cells (Boshoff and Weiss,
2002; Gallo, 1998). Since KS could present itself as a mul-
tifocal disease, and KS spindle cells express the hemato-
poietic stem cell marker CD34, it has been proposed that
the KS progenitor cell is a circulating cell of the hemato-
poietic endothelial lineage (Barozzi et al., 2003; Boshoff
and Weiss, 2002; Browning et al., 1994). Spindle cells in
the lesions express markers characteristic of the lym-
phatic endothelial cell (EC) lineage, such as LYVE-1, po-
doplanin, and VEGF-R3. It has been recently suggested
that they originate from lymphatic endothelium (Dupin
et al., 1999; Skobe et al., 1999), transdifferentiated vascu-
lar endothelium, or a common EC precursor (Hong et al.,
2004; Wang et al., 2004).
It is now well established that KSHV is an etiologic co-
factor strictly necessary for KS (Boshoff and Weiss,
1998; Chang et al., 1994; Ganem, 2006), indicating that
KSHV genetic expression is responsible for the KS angio-
genic phenotype. Although the KSHV genome encodes
for genes that can induce cell transformation (Gao et al.,
1997; Lee et al., 1998; Wang et al., 2006), immune dereg-
ulation (Moore et al., 1996; Nicholas et al., 1997), and an-
giogenesis activation (Aoki et al., 1999; Bais et al., 1998,
2003; Boshoff et al., 1997; Montaner et al., 2003; Yang
et al., 2000), KSHV infection leads to KS in limited circum-
stances.
Since KSHV is an endothelial-tropic virus, several
KSHV-infection models using ECs have been described
(Ciufo et al., 2001; Flore et al., 1998; Hong et al., 2004;
Lagunoff et al., 2002; Moses et al., 1999; Naranatt et al.,
2004; Wang et al., 2004). In contrast to the oncogenicity
and tumorigenicity of its viral genome, KSHV infection of
ECs leads to the induction of KS markers, a spindle cell
phenotype, and signs of transformation, but it does not
result in the acute angiogenicity and tumorigenicity char-
acteristic of KSHV-infected spindle cells in lesions. This246 Cancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc.suggests that key oncogenic events are not recapitulated
in the KSHV-infected EC cultures. Plausible explanations
for this are the tendency for either latency or productivity
of the in vitro infections, the possibility that terminally dif-
ferentiated ECs may not be suitable KS progenitors, or
that in vivo growth conditions not mimicked in culture
are essential for KSHV oncogenicity.
Here, we report that bacterial artificial chromosome
(KSHVBac36) transfection of normal mouse bone marrow
endothelial-lineage cells induces an angiogenic pheno-
type and KS-like, KSHV-dependent tumorigenicity. This
identifies a cell population containing putative KS progen-
itors and establishes a KS model with the following
characteristics: (1) the pathological phenotype is a conse-
quence of KSHV gene expression in normal progenitor
cells subjected to in vivo growth conditions, (2) the histo-
pathologic phenotype of the tumors resembles KS le-
sions, and (3) the model is suitable for genetic analysis
of viral pathogenesis.
RESULTS
Bac36 Transfection of Mouse Bone Marrow
Endothelial Hematopoietic Cells Leads to KSHV
Latent and Lytic Gene Expression
To create a mouse model of KS, we used as targets of
KSHV infection mouse bone marrow adherent-cell prepa-
rations enriched in endothelial-lineage cells (mECs) con-
taining mature ECs, their progenitors, and proangiogenic
hematopoietic cells (Boshoff and Weiss, 2002; Rafii and
Lyden, 2003). To be able to select and track infected cells,
we transfected mECs with KSHVBac36, which encodes
the full infectious KSHV genome in a hygromycin (Hyg)-
resistant and EGFP-encoding bacterial artificial chromo-
some (KSHVBac36) (Zhou et al., 2002). mECs transfected
with the Bac backbone vector (mEC-V) were used as con-
trol. After 3 weeks of Hyg selection, both KSHVBac36-
transfected mECs (mECK36) and mEC-V formed con-
tact-inhibited, stromal cell-like monolayers. We found
that mECK36 cultures were over 95% EGFP+ (Figure 1A),
indicating the presence of KSHVBac36. To determine if
the EGFP+ cell population was infected by KSHV, we an-
alyzed the expression of the latent genes LANA and Kapo-
sin by immunofluorescence. As shown in Figures 1A and
1B, all EGFP+ mECK36 were positive for LANA and dis-
played the classic nuclear punctuated pattern produced
by the tethering of KSHV episomes to the host chromo-
some (Ballestas et al., 1999). As shown in Figure 1C,
mECK36 also stained for the latent oncogene Kaposin
(Muralidhar et al., 1998) and displayed its characteristic
perinuclear localization.
To estimate the integrity of the KSHV genome in
mECK36, we performed real-time RT-PCR analysis for
the entire KSHV transcriptome of mECK36 (Dittmer,
2003; Fakhari and Dittmer, 2002). We compared the
expression pattern in the endothelial-lineage (mECK36)
cells with non-KSHV targets (Bac36-transfected NIH 3T3
cells) (C.C., A.D.M., and E.A.M., unpublished data).
mRNA levels were 218-fold higher (CV: 45.391, n = 100,
Cancer Cell
Animal Model of KSHV-Induced Kaposi’s SarcomaFigure 1. KSHVBac36 Transfection of Mouse Bone Marrow Endothelial Hematopoietic Cells Leads to KSHV Latent and Lytic Gene
Expression
(A) Immunofluorescence staining of LANA.
(B) Confocal image showing punctuated LANA staining.
(C) Immunofluorescence staining of Kaposin.
(D) Immunofluorescence staining of K8.1 and LANA.
(E) Detailed confocal image of LANA and K8.1.
(F) Heatmap representation of real-time RT-PCR analysis for the entire KSHV transcriptome in Bac36KSHV-transfected cells. Ctrl, mock-transfected
NIH 3T3 cells. Red indicates the highest, yellow indicates intermediate, and black indicates the lowest relative mRNA levels. The scale bar is 10 mM.p% 1014) in mECK36 than in Bac36-transfected NIH 3T3
cells. In contrast, KSHV latent mRNAs (LANA, lat273f,
orf72, Taq-F4, 73-50UTR, orf72f1) were present at about
equal levels, with a mean difference of 2.24-fold
(CV: 1.04.5.51, n = 6, p % 0.29). This shows that
mECK36 have increased lytic gene expression. All KSHV
genes are expressed over background levels (Figure 1F),
indicating that the KSHV transcriptome is complete in
mECK36, further suggesting that the Bac has not under-
gone major deletions or translocations that would affect
KSHV gene expression.
Although lytic gene transcription in mECK36 is abun-
dant, they did not produce KSHV virions, as indicated by
transmission electron microscopy analysis and the ab-
sence of a cytopathic effect (CPE) (data not shown). Dou-
ble immunofluorescence staining for the latent antigen
LANA and the late lytic antigen K8.1 shows a coexpressionCpattern (Figures 1D and 1E) in most of the cells, which,
together with the mECK36 KSHV transcription profile, is
indicative of an abortive lytic transcription status.
KSHVBac36-Transfected Bone Marrow
Endothelial-Lineage Cells Are Angiogenic
The abortive lytic status of mECK36 is expected to be
highly oncogenic, since it combines the expression of la-
tent and lytic KSHV genes with transforming and angio-
genesis-inducing potential. Both mEC-V and mECK36 be-
came immortalized in culture and could be passaged
infinitely (current passages > 50). Since murine cells ex-
press telomerase, they generally become immortalized
as a consequence of cell culture shock (Sherr and
DePinho, 2000). KSHV genes can upregulate telomerase
expression (Knight et al., 2001); therefore, we tested
telomerase activity in mEC-V and mECK36 and foundancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc. 247
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Animal Model of KSHV-Induced Kaposi’s SarcomaFigure 2. KSHVBac36 Transfection of
mECs Induces an Angiogenic Phenotype
(A) ELISA-based Telomerase Repeat Amplifi-
cation Protocol (TRAP) assay of mEC-V and
mECK36. Bars indicate mean of duplicates ±
SEM.
(B) VEGF secretion levels of mEC-V and
mECK36. Bars indicate mean of duplicates ±
SEM.
(C) Intradermal skin angiogenesis assay (see
Experimental Procedures) of mEC-V and
mECK36. The bar graphs show the mean mi-
crovessel density (vessels/mm2)3 100 ± SEM.
Total n (both flanks) = 10. (***p < 0.05).
(D) KSHVBac36-induced upregulation of an-
giogenic gene expression determined by real-
time qRT-PCR. Bars represent mean fold in-
crease (triplicates ± SEM) in mRNA levels
between mECK36 and mECs.
(E) Appearance at a dissected inoculation site
in the skin of a mouse injected with mECs or
mECK36.increased levels in mECK36 (Figure 2A). Transformed cells
have increased telomerase expression; yet, the finding
that mECK36 were contact inhibited suggested that they
were not transformed. To identify transformed clones
among the mECK36 population, we carried out an anchor-
age-independent growth assay in soft agar by using NIH
3T3 and RasV12-transformed NIH 3T3 cells as negative
and positive controls, respectively. While 92% of the
RasV12-transformed NIH 3T3 cells formed colonies in
soft agar, neither mECK36, mEC-V, nor control NIH 3T3
cells formed colonies, suggesting that mECK36 are not
transformed. To investigate KSHVBac36-induced angio-
genicity, we determined VEGF secretion levels, mRNA
expression of angiogenic markers, and skin angiogenicity
in mEC-V and mECK36. As shown in Figures 2B–2E,
KSHVBac36 transfection of mECs increased VEGF secre-
tion levels, upregulated ligands and receptors of the VEGF
and Angiopoietin family, and displayed a significantly in-
creased ability (p < 0.05) to induce microvessel formation
in mice skin. Taken together, these results indicate that248 Cancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc.KSHV expression in mECs induces an angiogenic pheno-
type.
KSHVBac36-Transfected Bone Marrow Endothelial
Hematopoietic Cells Form KSHV-Infected Tumors
that Resemble Kaposi’s Sarcoma
Cell angiogenicity is key for tumor growth. To determine if
mECK36 were tumorigenic in mice, they were injected
subcutaneously in nude mice by using mEC-V as controls.
We found that mECK36 formed solid tumors 3 weeks after
injection, in contrast to mEC-V, which did not (Figures 3A–
3C). Upon dissection, we found that the tumors were green-
yellow, indicating a significant percentage of EGFP+ cells
(Figure 3B). Tumors were analyzed in a blind fashion and
were found to be ‘‘vascularized spindle cell sarcomas,’’
which is the histological presentation of human KS tumors
(Figure 3D). Advanced invasive KS often appears as mul-
tifocal lesions on the lungs and the gastrointestinal tract
(Safai et al., 1985). To determine whether mECK36 could
also induce invasive KS, we injected passage 30 cellsFigure 3. mECK36 Induce Vascularized
Spindle Cell Sarcomas in Immunocom-
promised Mice
(A) Mice showing a subcutaneous mECK36
tumor 4 weeks after inoculation.
(B) Dissection site showing a green-yellow
tumor (EGFP expression).
(C) Subcutaneous tumor growth in nude mice
injected with mECK36 (closed circles) or
mEC-V (open squares). Data indicate mean
tumor size (n = 7) ± SEM.
(D) Microscopic image of a histological section
of a mECK36 tumor stained with hematoxylin
and eosin (H&E). V, microvessel.
(E) Image of a spindle cell sarcoma foci (T)
growing in the lung (L) stained with H&E.
(F) Image of a spindle cell tumor in the lungs
stained with H&E. E, blood extravasation; V,
microvessel. The scale bar is 50 mM.
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Animal Model of KSHV-Induced Kaposi’s SarcomaFigure 4. mECK36 Induce KSHV-Bearing Spindle Cell Sarcomas Resembling KS Tumors
(A) Dissected mouse showing subcutaneous fluorescent tumor observed under long-wave UV light.
(B) LANA immunohistochemistry of paraffin-embedded mECK36 tumors. The scale bar is 50 mM.
(C) Rat IgG control for LANA immuohistochemistry. The scale bar is 50 mM.
(D) Top left: confocal images showing podoplanin staining in the cytoplasm and LANA staining in the nucleus. Top right: higher-magnification image
showing the speckled pattern of LANA immunofluorescence in podoplanin+ cells. Bottom left: colocalization of LANA with EGFP. Bottom right: an
isotype-matched control. The scale bar is 10 mM.
(E) Confocal images showing K8.1 staining in the membrane (left) and colocalizing with EGFP (middle). (Right) Mouse IgG control. The scale bar is
10 mM.
(F) Heatmap representation of KSHV transcriptome in mECK36 tumors and mECK36 grown in culture quantified by using real-time qRT-PCR. C,
mECK36 grown in culture; T1, T2, and T3, primary mECK36 tumors. Red indicates the highest, yellow indicates intermediate, and black indicates
the lowest relative mRNA levels.intravenously in irradiated SCID/NOD mice. A total of
3 months after injection, mECK36-injected animals were
sick, while mEC-V-injected animals did not show any
signs of ailment. Necropsy of mECK36-injected animals
revealed multifocal, invasive spindle cell sarcoma lesionsCin lungs (9–20 foci per lung) (Figures 3E and 3F), a presen-
tation reminiscent of advanced visceral KS.
The fact that subcutaneous tumors showed strong
EGFP fluorescence (Figure 4A) indicated the presence of
mECK36 in the tumors. Although mECK36 did not displayancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc. 249
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Animal Model of KSHV-Induced Kaposi’s SarcomaFigure 5. mECK36 Spindle Cell Sarco-
mas Express KS and Angiogenic
Markers
(A) Frozen sections of tumors stained with indi-
cated antibodies. The scale bar is 50 mM.
(B) Paraffin-embedded tissue sections stained
with the indicated antibody and developed
with Cy3-conjugated anti-IgG. The scale bar
is 10 mM.
(C) Side and forward scatter of VEGF receptors
on single-cell suspensions from mECK36 tu-
mors by flow cytometry.
(D) Cells double positive for EGFP and indi-
cated VEGFR from tumors in (C).
(E) Percentage of cells expressing VEGFR
among the EGFP+ (black bars) and EGFR
(white bars) population.
(F) Upregulation of angiogenic gene expres-
sion in mECK36 tumors compared to cultured
mECK36. Bars represent mean fold increase
(triplicates ± SEM) in mRNA levels quantified
by real-time qRT-PCR.typical signs of cell transformation in vitro, they were ma-
lignant in vivo, forming vascularized tumors that led to
significant morbidity and mortality. To determine the pres-
ence of KSHV in the EGFP+ spindle cells of mECK36
tumors, we carried out immunohistochemical determina-
tion of KSHV LANA expression. Figures 4B and 4C show
that LANA+ cells comprise 30%–50% of mECK36 tumors,
which is also reminiscent of KS lesions (Dupin et al., 1999).
To further characterize the phenotype of the KSHV-
harboring cells in tumors and the status of their KSHV in-
fection, we costained for KSHV LANA, podoplanin, and
K8.1. All EGFP+ cells coexpressed LANA and podoplanin
(Figure 4B). Confocal images at different Z planes re-
vealed that up to 90% of nuclei were LANA+ and dis-
played the punctuated pattern indicative of episomal in-
fection (Figure 4D). More than 20% of the tumor cells
were also K8.1+ (Figure 4E). To determine changes in
the status of KSHV infection in mECK36 due to in vivo
growth conditions, we compared the KSHV transcription
profiles from three different tumors and from mECK36 in
culture (Figure 4F) normalized for LANA in order to include
only KSHV-harboring cells (Dittmer, 2003). Compared
to cultured mECK36, the tumors showed a 15.6-fold
increased expression of lytic genes versus a 1.1-fold in-
crease of latent genes. Since the average variation among250 Cancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc.the three tumors was only 2.13-fold (CV: 1.93.2.33, n = 91),
the increase in lytic mRNA levels must represent a biolog-
ical response of the viral genome to in vivo growth con-
ditions, rather than a variation introduced by intertumor
variation. Despite increased lytic transcription, mECK36
did not show increased viral genome replication, evi-
denced by the lack of variations in the KSHV viral load
and the absence of KSHV virions in the tumors (data not
shown). These data indicate that, similar to mECK36 in
culture, mECK36 tumors express latent and lytic genes,
consistent with an abortive lytic infection, but display in-
creased expression of KSHV lytic genes.
mECK36 Tumors Express KS
and Angiogenic Markers
To further determine if the phenotypic markers of the
mECK36 sarcomas corresponded to those typically found
in human KS lesions, we immunostained for CD31/
PECAM (pan-EC marker), VEGF-R2 (EPCs, angiogenically
active vessels, KS), and CD34 (EPC, microvascular endo-
thelium, and KS) (Boshoff and Weiss, 2002; Brown et al.,
1996; Rafii and Lyden, 2003). The presentation of these
markers (Figure 5A) corresponded to a highly vascularized
tumor (CD31+ vessels) bearing some VEGF-R2+ vessels
as well as VEGF-R2+ and CD34+ cells. To assess the
Cancer Cell
Animal Model of KSHV-Induced Kaposi’s Sarcomaexpression of VEGF receptors in EGFP+ cells, we used
immunofluorescence and cytofluorometry analysis for
the VEGF-R1 (ECs, proangiogenic hematopoietic cells),
VEGF-R2, and VEGF-R3 (lymphatic endothelium and KS)
(Hong et al., 2004; Rafii and Lyden, 2003; Wang et al.,
2004). A significant percentage of EGFP+ cells displayed
the KS and angiogenic markers VEGF-R1, VEGF-R2,
and VEGF-R3 (Figure 5A). Cytofluorometric determina-
tions of a representative tumor also showed that EGFP+
cells, which comprised 42% of the tumor, were 60%,
45%, and 40% VEGF-R1+, VEGF-R2+, and VEGF-R3+,
respectively (Figures 5D and 5E), compared to 1.5%,
2.0%, and 4.0% of EGFP cells, comprised by endothe-
lial and stromal cells from the tumor (Figure 5E). To assess
the possible upregulation of this angiogenic phenotype in
vivo, mRNA levels of VEGF and Angiopoietin family li-
gands and receptors in mECK36 grown in culture and
from nude mice tumors were quantified by real-time RT-
PCR. Most of the angiogenic mediators that were upregu-
lated by KSHVBac36 transfection were further upregu-
lated in mECK36 tumors (Figures 2D and 5F). These
results indicate that KSHV infection synergizes with in
vivo growth conditions to induce the expression of an
angiogenic phenotype reminiscent of KS.
mECK36 Mouse Spindle Cell Sarcomas Display
KSHV and Host Transcription Profiles
Reminiscent of Kaposi’s Sarcoma
To gain a perspective of how closely mECK36 KS-like sar-
comas resemble primary KS lesions from the standpoint
of KSHV expression, we compared the pattern of KSHV
transcription in mECK36 sarcomas and in biopsies from
KS lesions. By merging data reported here with data
from our previous study (Dittmer, 2003), we found that
the three mECK36 tumors grouped together, indicating
the high reproducibility of the mouse sarcomas (Figure 6A).
Six of the primary KS lesions clustered closer to the
mECK36 mouse tumors than the five other KS lesions,
which, in turn, clustered with cultured mECK36. These re-
sults indicate that the pattern of KSHV gene expression
obtained in mECK36 cultures and tumors can be consid-
ered representative of subpopulations defined by different
degrees of lytic gene expression that are found among KS
human tumors.
Molecular signatures are a useful way of evaluating the
phenotypic identity of tumors (Klein et al., 2001). The KS
signature was recently established by identifying 1256
KS genes (1482 probes) that differentiate KS and skin
sample groups (Wang et al., 2004). This group of differen-
tially expressed genes is thought to determine key pheno-
typic differences defining KS, and thus they are primary to
the biology of KS tumors. To evaluate the extent to which
our mouse model mimics the KS signature, we first deter-
mined the transcriptional profile of mECK36 tumors by us-
ing genomic arrays, and we identified which genes of the
human KS signature were able to differentiate mECK36 tu-
mors and mouse skin (q < 0.05) (Figure 6B), defining the
mouse KS-like signature. Then, we compared the human
and mouse KS-like signature and found that 81% of thetranscripts, including many key genes for KS pathophysi-
ology, were equally up- or downregulated in human KS
and mouse mECK36 tumors compared to skin (Figure 6B).
Using mEC-V, mECK36, and mECK36 tumor microarray
data to determine the degree of contribution to the KS-
like signature indicates that the major contribution to the
signature—close to 50%—was by mECK36 tumors (Fig-
ure 6C). In agreement with this microarray analysis, real-
time qRT-PCR comparison of angiogenesis-mediating
gene expression in mECK36 tumors, cultured mECK36,
and mEC-V (Figure 6D) shows that most of the angiogenic
gene upregulation takes place when mECK36 grow in vivo
to form tumors. Taken together, these results show that
KSHV is sufficient to confer to infected cells in vivo angio-
genic, tumorigenic, and phenotypic characteristics of KS.
mECK36 Belong to the Endothelial Cell Lineage
The KS-like phenotype of mECK36 tumors suggests that
Bac36 was originally transfected to a cell lineage closely
related to the one that leads to KS in human KSHV infec-
tion. More accurate determination of the cell lineage that
gave rise to mECK36 could point to a KS spindle cell pro-
genitor. Genomic profiling provides a useful way to trace
the cell of origin of transformed cells (Klein et al., 2001).
To further identify the progenitor(s) cell type that was
targeted by KSHVBac36 transfection among the hetero-
geneous mEC population, we used the genome-wide
transcription profile of mEC-V and mECK36 and clustered
it to several mouse cell types that can be present in the
mECs, including ECs, endothelial progenitors, and hema-
topoietic progenitors. As shown in Figure S1 (see the Sup-
plemental Data available with this article online), mEC-V
and mECK36 cluster in between endothelial progenitors
and mature vascular ECs, further supporting the endothe-
lial-lineage origin of mECK36.
mECK36 Tumorigenicity Is Reversible
and Strictly KSHV Dependent
mECK36 cultures and tumors are a valuable tool for defin-
ing the function of KSHV pathogenic genes and their rela-
tionship with host responses and KSHV biology. The phe-
notypic differences between mEC-V and mECK36 is
thought to be a consequence of KSHVBac36 transfection
with concomitant KSHV gene expression in normal cell
progenitors, and it is consistent with the proposed KSHV-
induced phenotype in KS. However, to demonstrate a link
between KSHV and mECK36 tumorigenesis, it is neces-
sary to show the dependency between KSHV gene
expression and the KS-like phenotype. This is because
mECK36 could have accumulated host gene oncogenic
alterations that may contribute to the malignant pheno-
type independently of KSHV. This can be demonstrated
by showing that mECK36 that have lost the KSHV genome
lose the ability to form KS-like tumors. It was previously
shown that episomal KSHV is lost from cells in culture un-
less it is maintained by antibiotic selection (Grundhoff and
Ganem, 2004). Episomally infected mECK36 are routinely
selected in Hyg-containing media for the maintenance of
the Hygr KSHVBac36. To test whether mECK36 culturedCancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc. 251
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Animal Model of KSHV-Induced Kaposi’s SarcomaFigure 6. Viral and Host Global Gene Expression of mECK36 Tumors Resembles KS
(A) Clustering of primary KS with mEC-Bac36 tumors. The heatmap represents real-time qRT-PCR results. Tumors 5, 3, and 7 are three mECK36
spindle cell sarcomas. BCBL Mock and TPA are BCBL-1 uninduced and induced with TPA, respectively.
(B) Heatmap representation of 562 genes (q < 0.05) of the human KS signature that behave as the mECK36 tumor signature (equally up- or down-
regulated). A total of 723 genes from the human KS signature were orthologs to mouse genes present in the mouse affymetrix array. Among these,
691 genes were able to differentiate mECK36 spindle cell sarcomas and mouse skin (q < 0.05) for at least a 2-fold difference. A total of 471 genes
(68%) and 91 genes (13%) were upregulated (red) and downregulated (blue), respectively, in both mECK36 tumors and human KS. Selected down-
regulated genes are shown in blue, and upregulated genes are shown in red. The full list of genes is available in Table S1.
(C) Distribution of the mouse KS signature. Blue, genes shared between mECK36 tumors and mEC-V; yellow, genes shared between mECK36 tumors
and mECK36 in culture; Olive, genes shared by mEC-V, mECK36 in culture, and tumors; Red, mECK36 tumors only. Gene intensity from the mouse
KS signature was set to 100%, and the percentage of genes that contribute to the mouse KS signature was calculated by using a 10% difference in
intensity between the different samples and tumors (GeneSpring 7 package).
(D) Angiogenic gene expression in mEC-V and in mECK36 relative to that in mECK36 tumors. mRNA levels were determined by real-time qRT-PCR.
mRNA levels in tumors were set at 100% (closed bar). Overlapped are bars representing relative mRNA levels in mECK36 in culture (gray bars) and in
mEC-V (open bars) (mean of triplicates ± SEM). Relative levels were calculated as a (1/fold increase in tumors) 3 100.in the absence of antibiotic selection lose the KSHVBac36
episome, cultured mECK36 and mECK36 explanted from
tumors were cultured in the presence or the absence of252 Cancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc.Hyg. We found that both mECK36 and explanted
mECK36 tumor cells lost the BacKSHV episome after 4
weeks of culture without Hyg, as evidenced by loss of
Cancer Cell
Animal Model of KSHV-Induced Kaposi’s SarcomaFigure 7. mECK36 Tumorigenicity Is
Reversible and Strictly KSHV Dependent
(A) Many cells in colonies that originated from
a single EGFP+ mECK36 became EGFP
when grown in the absence of Hyg.
(B) EGFP levels of cultured and explanted
mECK36 grown with or without Hyg deter-
mined by flow cytometry. mECK36 grown in
Hyg media were used as controls and were
set at 100% for every passage.
(C) In vitro growth rate of mECK36, mEC-V, and
KSHV null mECK36. Doubling times were 22,
14, and 15 hr, respectively.
(D) Tumor formation of KSHV null mECK36
(open circles), mECK36 (closed circles), and
a 1:1000 ratio of mECK36:KSHV null mECK36
(open triangles). Data indicate mean tumor
size ± SEM (n = 5). The scale bar is 100 mM.EGFP fluorescence (Figures 7A and 7B). To demonstrate
that this effect was actual episome loss and not outgrowth
by EGFP cells, we carried out a colony formation assay
in plastic, in which we monitored colonies originated from
a single EGFP+ mECK36. EGFP+ mECK36 single-cell
clones grown without Hyg lost their episomes and be-
came EGFP as they divided (Figure 7A, peripheral cells).
These results have several implications: (1) the rapid loss
of the episome in vitro suggests that mECK36 that lost
the KSHV episome had a selective advantage over
KSHV+ cells; (2) the generation of nonfluorescent and
Hyg-sensitive cultured and tumor-explanted cells indi-
cates that the KSHVBac36 is only present as an episome
and is not integrated in the host genome; (3) KSHV pro-
vides an in vivo selective advantage equivalent to Hyg
in vitro since mECK36 explanted from the tumor lose the
episome and tumors are grown in the absence of Hyg.
We compared KSHV+ mECK36 with mECK36 that have
lost the KSHV episome (KSHV null mECK36). While
KSHV null mECK36 or mEC-V have a higher growth rate
in vitro than mECK36 (Figure 7C), KSHV null mECK36
completely lost tumorigenicity in mice. Moreover, a mix-
ture of 1:1000 of mECK36:KSHV null mECK36 have de-
layed tumor growth in mice, which leads to the formation
of tumors similar in size to those induced by mECK36
alone (Figure 7D). Analysis of these tumors shows up to
30% EGFP+/KSHV LANA+ mECK36 (data not shown).
These results demonstrate that KSHV provides a selective
advantage in vivo, but not in vitro, and that mECK36 tu-
morigenesis is strictly dependent on KSHV since it can
be reversed by loss of the KSHV episome.
Role of KSHV Gene Expression and the Angiogenic
Oncogene vGPCR in Sarcomagenesis
KSHV dependency suggests that mECK36 tumors are
a biologically sensitive model in which we can study the
role of KSHV genes in KS pathogenesis. A mechanistic ex-
planation for mECK36 tumorigenesis is that KSHV genesupregulated during in vivo growth induce mECK36’s
malignancy by activating cell proliferation, cell survival,
or angiogenic gene expression (Figures 5F and 6D). We
found that the KSHV genes most upregulated when
mECK36 form tumors encode for proteins that have
been implicated in inhibition of p53-induced apoptosis
(vIRF-1) (Nakamura et al., 2001), JNK signaling (ORF36)
(Hamza et al., 2004), and angiogenesis activation (vGPCR)
(Figure 8A). Since vGPCR has been shown to induce a KS-
like angiogenic phenotype by activating VEGF expression
(Bais et al., 1998, 2003; Grisotto et al., 2006; Guo et al.,
2003; Montaner et al., 2003, 2006; Yang et al., 2000), we
speculated on the possibility that vGPCR upregulation
leading to VEGF secretion was causally linked to
mECK36 tumorigenesis. As a proof of principle for the
use of mECK36 in genetic studies of KSHV pathogenesis,
we silenced vGPCR by RNA interference (RNAi) by using
a vGPCR short hairpin RNA (shRNA) (Figure 8B) and as-
sessed the impact on mECK36 angiogenesis and tumori-
genicity. To determine whether the RNAi suppression
affected other KSHV pathogenic genes, we performed
real-time RT PCR array analysis on shRNA or control
transfected mECK36 (Figure 8C). While the level for most
of the KSHV mRNAs remained unchanged, as evidenced
by the clustering of data points on the 45 line (m = 1.00,
r2 = 0.95, n = 93), the vGPCR message was reduced
117-fold. We also observed a reduction of the mRNAs
for ORFs 7, 25, 26, and 27. The significant decrease on
the mRNA levels of these ORFs strongly suggests that cel-
lular signaling pathways activated by vGPCR might, in
turn, feed back on the virus to control the expression of
these KSHV genes. shRNA-mediated silencing of vGPCR
in mECK36 blocked their ability to secrete VEGF and sig-
nificantly reduced the ability of the mECK36 to induce mi-
crovessel formation in skin (Figure 8D) (p < 0.05). Although
both vGPCR shRNA and control shRNA-transfected
mECK36 grew at a very similar rate in culture (not shown),
vGPCR shRNA mECK36 tumors showed delay andCancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc. 253
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KSHV vGPCR in mECK36 Blocks Angio-
genicity and Tumorigenesis
(A) Increase in mRNA level of KSHV genes
in mECK36 tumors compared to cultured
mECK36 determined by real-time qRT-PCR.
Mean values (±SD) from three tumor samples
were plotted.
(B) RT-PCR analysis of vGPCR and GAPDH for
mECK36 transfected with control shRNA and
vGPCR shRNA vector.
(C) Log2 scale plot (dCT) of the actin-normal-
ized KSHV mRNA levels of mECK36 trans-
fected with control shRNA (horizontal) or
vGPCR shRNA (vertical). The arrows indicate
transcripts that are specifically downregulated,
and the annotation shows the identity and fold
downregulation.
(D) Left panel: levels of VEGF secretion for
mECK36 transfected with either control shRNA
or vGPCR shRNA vector measured by ELISA.
Bars indicate mean of duplicate measures ±
range. Right panel: angiogenesis in skin for
mEC-V, mECK36, mECK36 transfected with
either control shRNA or vGPCR shRNA vector.
The bar graphs show the mean microvessel
density (vessels/mm2) ± SEM. Total n (both
flanks) = 10. ***Significant differences between
vGPCR RNAi and control RNAi groups (p <
0.05) (n = 10).
(E) Tumor formation of mECK36 transfected
with control shRNA (closed circles) or with
vGPCR shRNA vector (open squares). Data in-
dicate mean tumor size ± SEM (n = 10).
(F) Tumor appearance after dissection and
lighting by using a long-wave UV lamp for
mECK36 transfected with control shRNA or
with vGPCR shRNA vector.inhibition in tumor formation (Figure 8E), which is consis-
tent with a reduction in angiogenicity (Folkman, 1995).
These results show that activation of angiogenesis by
KSHV vGPCR is causally implicated in mECK36 tumori-
genesis and demonstrate that mECK36 can be genetically
manipulated to study KSHV pathobiology.
DISCUSSION
A normal progenitor cell derivative containing the entire
KSHV genome allowed for the reproduction of the tumor-
igenic and angiogenic characteristics of an infected KS
spindle cell and led to the generation of a cell and animal
model of KSHV-induced KS. This model not only illustrates
several features that makes it useful for biological and pre-
clinical studies, but it also challenges our current thinking
on key issues of KSHV biology and KS pathogenesis.254 Cancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc.We found that the KSHV genome is angiogenic and tu-
morigenic in endothelial-lineage cells of adherent bone
marrow cell preparations. These findings suggest that an
endothelial-lineage cell type is a natural target of KSHV in-
fection and a progenitor of tumorigenic KS spindle cells. It
should be added that although our approach allows us to
‘‘target’’ putative progenitors in the transfected population
and may have been critical for inclusion of the right cell
type(s) in the right microenvironment, it does not allow
us to unequivocally identify the KSHV targets. Never-
theless, phenotypic marker expression and transcriptome
profile clustering results are consistent with the KSHVBac36
being transfected to endothelial-lineage cells that are
among the bone marrow adherent-cell population, includ-
ing ECs and EC progenitors (Rafii and Lyden, 2003).
We showed that the KSHV genome can independently
induce the KS phenotype when its genome is expressed
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Animal Model of KSHV-Induced Kaposi’s Sarcomawithin the context of an appropriate normal cell progenitor
and when the KSHV-bearing cells are grown in vivo.
mECK36 lead to the growth of subcutaneous tumors or
multifocal KS pulmonary lesions consisting of vascular
spindle cell sarcomas that expressed angiogenic and KS
phenotypic markers such as podoplanin and the VEGF
and Angiopoietin receptors and ligands. Moreover, ge-
nome-wide transcriptome analysis of mECK36 tumors
revealed that 81% of human KS signature genes behaved
as mECK36 tumor signature genes and were similarly up-
or downregulated in mouse and human tumors. These
findings suggest that the KSHV genome encodes the abil-
ity to recreate the full KS pathophysiology, including vis-
ceral invasiveness and disease localization.
The pattern of KSHV expression in tumors, as evi-
denced by RT-PCR array analysis and immunodetection
of K8.1, was consistent with an increase in lytic tran-
scripts. Although it was reported that most spindle cells
in KS lesions are latently infected (Staskus et al., 1997),
we found that a subpopulation of KS lesions (Dittmer,
2003) exhibits a pattern of KSHV expression similar to
mECK36 spindle sarcomas. Thus, the KSHV expression
profile of mECK36 in tumors can be biologically relevant.
In future studies, it will be of importance to establish pos-
sible correlations between the mECK36-like KSHV ex-
pression profile and KS clinical presentation. Interestingly
enough, the mECK36 pattern of KSHV gene expression
was not accompanied by virus production, indicating
that mECK36 were in an abortive lytic replication state.
Others have shown that in permissive human cells
KSHVBac36 transfection leads to virion production
(Zhou et al., 2002). In contrast, both in vitro and in vivo
grown mECK36 showed an absence of viral replication.
Since transcriptome analysis shows that the viral genome
is intact, it is unlikely that the defects in viral replication
were due to Bac36 alterations. Instead, viral replication
and maturation events are most likely being blocked. A re-
cent report (Parsons et al., 2006) points to productive
KSHV infection in SCID/NOD mice upon injection of
KSHV virions, suggesting that the use of KSHVBac36
transfection may relate to the abortive lytic status of
mECK36. Interestingly, KS lesions contain lytic replica-
tion-defective KSHV genomes that may play a role in KS
tumorigenesis (Deng et al., 2004). Thus, the replication-
defective infection achieved by Bac36 transfection may
be relevant to actual occurrences of the disease and might
have been critical to capture a KSHV-induced KS pheno-
type.
We found that KSHV episome loss led to loss of tumor-
igenicity. This indicates that the mECK36 tumorigenic
phenotype is strictly dependent on KSHV and reversible,
since mECK36 reverted to a nontumorigenic phenotype
upon KSHV loss in vitro. This resembles explanted KS
spindle cells that lose KSHV in culture and become nontu-
morigenic (Aluigi et al., 1996; Dictor et al., 1996; Ganem,
2006). It also suggests that KSHV-induced oncogenesis,
at least in its initial stages, does not lead to the accumula-
tion of additional oncogenic hits that could contribute to
a malignant phenotype independent of KSHV. This alsoresembles human KS lesions in which cellular oncogenic
alterations such as p53 and ras mutations, or Bcl-2 over-
expression together with increased clonality, tend to be
found only in advanced KS (Gill et al., 1998; Nicolaides
et al., 1994; Pillay et al., 1999; Rabkin et al., 1997). It can
also be concluded that the maintenance of the KSHV epi-
some during tumor formation—which is carried out in the
absence of Hyg—indicates that KSHV does provide a
selective advantage for in vivo growth that leads to tumor-
igenesis. This selective advantage of KSHV+ versus non-
infected cells provides an alternative explanation to rein-
fection (Grundhoff and Ganem, 2004) for maintenance of
the KSHV episome in infected spindle cells in KS lesions.
KSHVBac36-mediated tumorigenesis correlated with
the upregulation of several KSHV lytic transcripts and
the induction of a KS-like angiogenic phenotype upon im-
plantation into nude mice. This further supports the notion,
evidenced by recent publications, that in KS as well as in
PEL (An et al., 2006; Staudt et al., 2004) the host microen-
vironment influences KSHV gene expression. However,
the regulatory effects are indeed reciprocal. We found
that KSHV together with in vivo growth conditions trigger
in the infected cell the expression of genes related to an-
giogenesis and malignancy, which provides a selective
advantage and leads to tumor formation. We found that
mECK36 grown in vitro did not display signs of cell trans-
formation. When subjected to in vivo growth conditions,
however, the same cells induced angiogenic spindle cell
sarcomas with upregulation of key angiogenic markers
(Figures 5F and 6D). In concordance, analysis of the
mouse KS-like signature of mECK36 tumors showed
that almost 50% of it derives from genes that were only ex-
pressed in mECK36 tumors. The concomitant upregula-
tion of KSHV lytic genes in vivo and the induction of an an-
giogenic phenotype in KS-like lesions pointed to a series
of potentially pathogenic KSHV genes as critical determi-
nants of KS-like tumorigenesis. We selectively inhibited
one of these genes to prove its involvement in mECK36 tu-
morigenesis and to test the suitability of our model for ge-
netic analysis of KSHV pathogenic function. siRNA-medi-
ated suppression of the early lytic angiogenic oncogene
vGPCR (Bais et al., 1998, 2003; Yang et al., 2000) blocked
VEGF secretion and tumorigenesis, leading to significant
retardation in tumor growth. It is unlikely that siRNA was
also targeting the expression of ORF K14, which is coex-
pressed with vGPCR in bicistronic messages (Kirshner
et al., 1999), as ORF K14 mRNA levels were not affected
by the vGPCR shRNA (Figure 8C). These results with
vGPCR silencing were verified by preliminary studies
with vGPCR null Bac36 mutants (L.E.C. and E.A.M., un-
published data). Our results confirm single-gene experi-
ments with vGPCR (Bais et al., 1998, 2003; Grisotto
et al., 2006; Guo et al., 2003; Montaner et al., 2003,
2006; Yang et al., 2000), indicating that it plays a nonre-
dundant role in angiogenesis and tumorigenesis within
the context of full KSHV genome expression, and they
further support the notion that this KSHV gene is a good
therapeutic target. Our results with vGPCR suppression
show that our model is sensitive to genetic manipulationCancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc. 255
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genes in tumorigenesis. Furthermore, they point to
a mECK36 in vivo malignant phenotype as a consequence
of upregulation of KSHV genes, such as vGPCR, that
provide a selective advantage to the cell—in this case
angiogenicity—leading to positive selection of the KSHV
episome and KS-like tumor formation.
The suitability of mECK36 for genetic studies of KS
pathogenesis could help to reveal the role of both KSHV
and host genes implicated in the KS phenotype. A recent
report showed that long-term latent KSHV infection of im-
mortalized human ECs leads to the outgrowth of trans-
formed and tumorigenic clones (An et al., 2006). However,
the use of hTERT-immortalized cells as substrates, and
the sporadic occurrence of the in vitro-transformed out-
growths point to the accumulation of oncogenic alter-
ations in the host genome; thus, making it difficult to
strictly link the malignant phenotype to specific KSHV
genes. In our case, the fact that Bac36 transfection of
mECs leads to a nonproductive infection also imposes
limitations to the mECK36 model, in particular for studying
viral entry and viral replication. However, several key char-
acteristics make the mECK36 model appropriate for
genetic studies of pathobiology and experimental thera-
peutics: (1) the progenitor target population(s) is normal
mouse bone marrow cells, making it possible to use avail-
able knockout (KO) or conditional KO mice to generate
different Bac36-transfected cells that could be used to
identify genetic determinants of KS pathogenesis; (2) the
KSHV dependence of the KS phenotype makes the
mECK36 system highly sensitive for studies of KSHV
genes critical for tumor growth and makes it suitable for
testing therapeutic strategies targeting KSHV pathogenic
genes or host angiogenic machinery; (3) the mECK36 pop-
ulation expresses the full KSHV genetic complement, al-
lowing for manipulation of latent and lytic KSHV genes
by using Bac or siRNA in functional studies; (4) mECK36
viral expression was stable through multiple passages
(D.P.D. and E.A.M., unpublished data) and had reproduc-
ible in vivo pathogenic phenotypes.
In summary, our results show that the mEC Bac36 sys-
tem and the mECK36 KSHV-harboring spindle sarcomas
are good phenotypic, physiologic, molecular, and viral
surrogates of human KS that could unlock research
avenues for KSHV pathobiology. They define mECK36
as a biologically sensitive cell and animal model of viral
KS suitable for analyzing the role of KSHV and host cell
genes in KS pathogenesis, as well as for preclinical testing
of anti-KS drugs.
EXPERIMENTAL PROCEDURES
Vectors and Constructs
The empty vector pMHGP and the vector containing the insert with the
genome of KSHV in Bacterial Artificial Chromosome (KSHVBac36)
were obtained as described previously (Zhou et al., 2002). The empty
vector pSilencer 2.1-U6 neo and the shRNA control vector were ob-
tained from Ambion (Austin, TX). To obtain the hairpin sequences
that silence the expression of vGPCR, we selected candidate se-
quences for low homology to mouse transcripts by BLAST search.256 Cancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc.The selected sequences were 50-GATCCCATGTTCTTGGAAATGG
ATTTTCAAGAGAAATCCATTTCCAAGAACATTTTTTTGGAAA-30 and
50-AGCTTTTCCAAAAAATGTTCTTGGAAATGGATTTCTCTTGAAAAT
CCATTTCCAAGAACATGG-30, which created vGPCR shRNA hairpin
loops with BamHI- and HindIII-specific sticky ends to be cloned in pSi-
lencer 2.1-U6 neo. All of the transfections were performed by using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Cells transfected with
KSHVBac36 or vector were selected with Hyg-B. For pSilencer
2.1-U6 neo vGPCR or control vector, cells were double selected
with Hyg-B and G418 (Sigma, Saint Louis, Missouri).
Cells
mECs were obtained from Balb/C An Ncr-nu mice (NCI, Bethesda, MD)
bone marrow. Mice femurs were flushed twice with PBS, and the
eluates were incubated in DMEM media plus 30% FBS (Gemini Bio-
products, Calabasas, CA), 0.2 mg/ml Endothelial Growth Factor
(EGF) (Sigma, Saint Louis, MO), 0.2 mg/ml Endothelial Cell Growth
Factor Supplement (ECGS) (Sigma, Saint Louis, Missouri), 1.2 mg/
1 heparin (Sigma, Saint Louis, MO), insulin transferrin selenium (Invi-
trogen, Carlsbad, CA), 1% penicillin-streptomycin (Invitrogen, Carls-
bad, CA), and BME vitamin (VWR Scientific, Rochester, NY). NIH 3T3
cells were purchased from American Type Culture Collection.
RasV12-transformed NIH 3T3 cells were obtained as described (Bais
et al., 1998).
Animals
Eight-week-old male Balb/C An Ncr-nu mice (NCI, Bethesda, MD)
were used for angiogenesis assays and subcutaneous tumors.
Twelve-week-old male SCID/NOD ICRSC-M mice (Taconic, German-
town, NY) were used for intravenous injection of cells. Mice were kept
under sterile conditions and were used under protocols approved by
the Institutional Animal Care and Use Committee.
Angiogenesis Assay
A total of 3 3 105 cells (two inoculation sites per mouse) were inocu-
lated intradermally in Balb/C nude mice. Trypan blue (20%) was
used to assess cell viability and mark the inoculation site. Mice (five
per group) were sacrificed 5 days later, and the surface area of the in-
jection site was exposed by dissection and was photographed with
a stereoscopic microscope (Nikon Corporation, Tokyo, Japan). To as-
sess microvessel density, the whole surface area of the injection site
was examined for morphometric analysis by following Auerbach’s cri-
teria (Auerbach et al., 2000). To this extent, each photograph slide was
projected in a grid corresponding to 12 mm, and the total number of
individual blood microvessels on all grids was counted in a blinded la-
beled fashion. The blood density was defined as the number of vessels
per grid (D = total number of vessels/total number of grids counted).
Mouse Tumor Growth Assays
Mice (n = 7) were inoculated subcutaneously with cells (3 3 105 per
mouse). Tumor growth was followed by caliper measurements of vol-
ume until the date of sacrifice. mECK36 tumors were allowed to grow
until they reached a volume of 2 cm3. SCID/NOD mice (n = 5) were
irradiated (350 rad) and, after 3 hr, were inoculated intravenously (IV)
in the tail vein (23106 cells per mouse). Mice were followed for3 months
until symptoms of distress such as dyspnea and pain, at which point
they were sacrificed and complete necropsies were performed.
Other Experimental Procedures
For details on immunofluorescence, immunohistochemistry, real-time
qRT-PCR, VEGF Elisa, flow cytometry of tumor, microarray proce-
dures and analysis, and statistical methods, see Supplemental Data.
Supplemental Data
The Supplemental Data include Supplemental Experimental Pro-
cedures, one supplemental figure, and one supplemental table and
are available at http://www.cancercell.org/cgi/content/full/11/3/245/
DC1/.
Cancer Cell
Animal Model of KSHV-Induced Kaposi’s SarcomaACKNOWLEDGMENTS
This paper is dedicated to Philip Juan Browning (1953-2004), who
made the initial observations on the existence of circulating hemato-
poietic KS progenitors. We would like to thank Rafael Tejada and David
K. Jin for their help and support. We are grateful to Dr. Don Ganem for
his thoughtful critiques of earlier versions of this work and Dr. Ethel
Cesarman for her helpful comments and her continuous support of
our work. We are thankful to Dr. Beata Frydel and Brigitte Shaw from
the Imaging and Molecular Core Facility (DRI, University of Miami).
We thank Dr. Adam Asch, Dr. Roger Pierce, Anne Marie Valadere,
and Heidi Kiger for comments on the manuscript. We are indebted
to Aileen Chen for her excellent editing job. We are thankful to Drs. Da-
vid Salomon and Sunil Kurian for facilitating their array data sets. This
work was supported by National Institutes of Health grants CA 075918
to E.A.M, CA096512 to S.-J.G., and CA110136 and CA109232 to
D.P.D; by a grant from the Dorothy Rodbell Cohen Foundation for Sar-
coma Research to E.A.M.; and by the Viral Oncology Program of the
Sylvester Comprehensive Cancer Center (E.A.M.).
Received: June 7, 2006
Revised: October 13, 2006
Accepted: January 4, 2007
Published: March 12, 2007
REFERENCES
Aluigi, M.G., Albini, A., Carlone, S., Repetto, L., De Marchi, R., Icardi,
A., Moro, M., Noonan, D., and Benelli, R. (1996). KSHV sequences in
biopsies and cultured spindle cells of epidemic, iatrogenic and Medi-
terranean forms of Kaposi’s sarcoma. Res. Virol. 147, 267–275.
An, F.Q., Folarin, H.M., Compitello, N., Roth, J., Gerson, S.L., McCrae,
K.R., Fakhari, F.D., Dittmer, D.P., and Renne, R. (2006). Long-term-
infected telomerase-immortalized endothelial cells: a model for Kapo-
si’s sarcoma-associated herpesvirus latency in vitro and in vivo.
J. Virol. 80, 4833–4846.
Aoki, Y., Jaffe, E.S., Chang, Y., Jones, K., Teruya-Feldstein, J., Moore,
P.S., and Tosato, G. (1999). Angiogenesis and hematopoiesis induced
by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6.
Blood 93, 4034–4043.
Auerbach, R., Akhtar, N., Lewis, R.L., and Shinners, B.L. (2000). Angio-
genesis assays: problems and pitfalls. Cancer Metastasis Rev. 19,
167–172.
Bais, C., Santomasso, B., Coso, O., Arvanitakis, L., Raaka, E.G., Gut-
kind, J.S., Asch, A.S., Cesarman, E., Gershengorn, M.C., and Mesri,
E.A. (1998). G-protein-coupled receptor of Kaposi’s sarcoma-associ-
ated herpesvirus is a viral oncogene and angiogenesis activator.
Nature 391, 86–89.
Bais, C., Van Geelen, A., Eroles, P., Mutlu, A., Chiozzini, C., Dias, S.,
Silverstein, R., Rafii, S., and Mesri, E.A. (2003). Kaposi’s sarcoma as-
sociated herpesvirus G protein coupled receptor immortalizes human
endothelial cell by activation of the VEGF receptor-2/KDR. Cancer Cell
3, 131–143.
Ballestas, M.E., Chatis, P.A., and Kaye, K.M. (1999). Efficient per-
sistence of extrachromosomal KSHV DNA mediated by latency-
associated nuclear antigen. Science 284, 641–644.
Barozzi, P., Luppi, M., Facchetti, F., Mecucci, C., Alu, M., Sarid, R.,
Rasini, V., Ravazzini, L., Rossi, E., Festa, S., et al. (2003). Post-trans-
plant Kaposi sarcoma originates from the seeding of donor-derived
progenitors. Nat. Med. 9, 554–561.
Boshoff, C., and Weiss, R.A. (1998). Kaposi’s sarcoma-associated
herpesvirus. Adv. Cancer Res. 75, 57–86.
Boshoff, C., and Weiss, R. (2002). AIDS-related malignancies. Nat.
Rev. Cancer 2, 373–382.
Boshoff, C., Endo, Y., Collins, P.D., Takeuchi, Y., Reeves, J.D.,
Schweickart, V.L., Siani, M.A., Sasaki, T., Williams, T.J., Gray, P.W.,Cet al. (1997). Angiogenic and HIV-inhibitory functions of KSHV-
encoded chemokines. Science 278, 290–294.
Brown, L.F., Tognazzi, K., Dvorak, H.F., and Harrist, T.J. (1996). Strong
expression of kinase insert domain-containing receptor, a vascular
permeability factor/vascular endothelial growth factor receptor in
AIDS-associated Kaposi’s sarcoma and cutaneous angiosarcoma.
Am. J. Pathol. 148, 1065–1074.
Browning, P.J., Sechler, J.M.G., Kaplan, M., Washington, R.H., Gen-
delman, R., Yarchoan, R., Ensoli, B., and Gallo, R.C. (1994). Identi-
fication and culture of Kaposi’s sarcoma-like spindle cells from the
peripheral blood of human immunodeficiency virus-1 individualas
and normal controls. Blood 84, 2711–2720.
Cesarman, E., Chang, Y., Moore, P.S., Said, J.W., and Knowles, D.M.
(1995). Kaposi’s sarcoma-associated herpes virus-like DNA se-
quences are present in AIDS-related body cavity B-cell lymphomas.
N. Engl. J. Med. 332, 1186–1191.
Chang, Y., Cesarman, E., Pessin, M.S., Lee, F., Culpepper, J.,
Knowles, D., and Moore, P. (1994). Identification of herpesvirus-like
DNA sequences in AIDS-associated Kaposis’s sarcoma. Science
266, 1865–1869.
Ciufo, D.M., Cannon, J.S., Poole, L.J., Wu, F.Y., Murray, P., Ambinder,
R.F., and Hayward, G.S. (2001). Spindle cell conversion by Kaposi’s
sarcoma-associated herpesvirus: formation of colonies and plaques
with mixed lytic and latent gene expression in infected primary dermal
microvascular endothelial cell cultures. J. Virol. 75, 5614–5626.
Deng, J.H., Zhang, Y.J., Wang, X.P., and Gao, S.J. (2004). Lytic repli-
cation-defective Kaposi’s sarcoma-associated herpesvirus: potential
role in infection and malignant transformation. J. Virol. 78, 11108–
11120.
Dictor, M., Rambech, E., Way, D., Witte, M., and Bendsoe, N. (1996).
Human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus)
DNA in Kaposi’s sarcoma lesions, AIDS Kaposi’s sarcoma cell lines,
endothelial Kaposi’s sarcoma simulators, and the skin of immunosup-
pressed patients. Am. J. Pathol. 148, 2009–2016.
Dittmer, D.P. (2003). Transcription profile of Kaposi’s sarcoma-associ-
ated herpesvirus in primary Kaposi’s sarcoma lesions as determined
by real-time PCR arrays. Cancer Res. 63, 2010–2015.
Dupin, N., Fisher, C., Kellam, P., Ariad, S., Tulliez, M., Franck, N., van
Marck, E., Salmon, D., Gorin, I., Escande, J.P., et al. (1999). Distribu-
tion of human herpesvirus-8 latently infected cells in Kaposi’s sar-
coma, multicentric Castleman’s disease, and primary effusion lym-
phoma. Proc. Natl. Acad. Sci. USA 96, 4546–4551.
Fakhari, F.D., and Dittmer, D.P. (2002). Charting latency transcripts in
Kaposi’s sarcoma-associated herpesvirus by whole-genome real-time
quantitative PCR. J. Virol. 76, 6213–6223.
Flore, O., Rafii, S., Ely, S., O’Leary, J.J., Hyjek, E.M., and Cesarman, E.
(1998). Transformation of primary human endothelial cells by Kaposi’s
sarcoma-associated herpesvirus. Nature 394, 588–592.
Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and
other disease. Nat. Med. 1, 27–31.
Gallo, R.C. (1998). The enigmas of Kaposi’s sarcoma. Science 282,
1837–1839.
Ganem, D. (2006). KSHV infection and the pathogenesis of Kaposi’s
sarcoma. Annu. Rev. Pathol. Mech. Dis. 1, 273–296.
Gao, S.J., Boshoff, C., Jayachandra, S., Weiss, R.A., Chang, Y., and
Moore, P.S. (1997). KSHV ORF K9 (vIRF) is an oncogene which inhibits
the interferon signaling pathway. Oncogene 15, 1979–1985.
Gill, P.S., Tsai, Y.C., Rao, A.P., Spruck, C.H., 3rd, Zheng, T., Harring-
ton, W.A., Jr., Cheung, T., Nathwani, B., and Jones, P.A. (1998). Evi-
dence for multiclonality in multicentric Kaposi’s sarcoma. Proc. Natl.
Acad. Sci. USA 95, 8257–8261.
Grisotto, M.G., Garin, A., Martin, A.P., Jensen, K.K., Chan, P., Sealfon,
S.C., and Lira, S.A. (2006). The human herpesvirus 8 chemokineancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc. 257
Cancer Cell
Animal Model of KSHV-Induced Kaposi’s Sarcomareceptor vGPCR triggers autonomous proliferation of endothelial cells.
J. Clin. Invest. 116, 1264–1273.
Grundhoff, A., and Ganem, D. (2004). Inefficient establishment of
KSHV latency suggests an additional role for continued lytic replication
in Kaposi sarcoma pathogenesis. J. Clin. Invest. 113, 124–136.
Guo, H.G., Sadowska, M., Reid, W., Tschachler, E., Hayward, G., and
Reitz, M. (2003). Kaposi’s sarcoma-like tumors in a human herpesvirus
8 ORF74 transgenic mouse. J. Virol. 77, 2631–2639.
Hamza, M.S., Reyes, R.A., Izumiya, Y., Wisdom, R., Kung, H.J., and
Luciw, P.A. (2004). ORF36 protein kinase of Kaposi’s sarcoma herpes-
virus activates the c-Jun N-terminal kinase signaling pathway. J. Biol.
Chem. 279, 38325–38330.
Hong, Y.K., Foreman, K., Shin, J.W., Hirakawa, S., Curry, C.L., Sage,
D.R., Libermann, T., Dezube, B.J., Fingeroth, J.D., and Detmar, M.
(2004). Lymphatic reprogramming of blood vascular endothelium by
Kaposi sarcoma-associated herpesvirus. Nat. Genet. 36, 683–685.
Kirshner, J.R., Staskus, K., Haase, A., Lagunoff, M., and Ganem, D.
(1999). Expression of the open reading frame 74 (G-protein-coupled
receptor) gene of Kaposi’s sarcoma (KS)-associated herpesvirus: im-
plications for KS pathogenesis. J. Virol. 73, 6006–6014.
Klein, U., Tu, Y., Stolovitzky, G.A., Mattioli, M., Cattoretti, G., Husson,
H., Freedman, A., Inghirami, G., Cro, L., Baldini, L., et al. (2001). Gene
expression profiling of B cell chronic lymphocytic leukemia reveals
a homogeneous phenotype related to memory B cells. J. Exp. Med.
194, 1625–1638.
Knight, J.S., Cotter, M.A., 2nd, and Robertson, E.S. (2001). The la-
tency-associated nuclear antigen of Kaposi’s sarcoma-associated
herpesvirus transactivates the telomerase reverse transcriptase pro-
moter. J. Biol. Chem. 276, 22971–22978.
Lagunoff, M., Bechtel, J., Venetsanakos, E., Roy, A.M., Abbey, N.,
Herndier, B., McMahon, M., and Ganem, D. (2002). De novo infection
and serial transmission of Kaposi’s sarcoma-associated herpesvirus in
cultured endothelial cells. J. Virol. 76, 2440–2448.
Lee, H., Veazey, R., Williams, K., Li, M., Guo, J., Neipel, F., Flecken-
stein, B., Lackner, A., Desrosiers, R.C., and Jung, J.U. (1998). Dereg-
ulation of cell growth by the K1 gene of Kaposi’s sarcoma-associated
herpesvirus. Nat. Med. 4, 435–440.
Montaner, S., Sodhi, A., Molinolo, A., Bugge, T.H., Sawai, E.T., He, Y.,
Li, Y., Ray, P.E., and Gutkind, J.S. (2003). Endothelial infection with
KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcoma-
genesis and can promote the tumorigenic potential of viral latent
genes. Cancer Cell 3, 23–36.
Montaner, S., Sodhi, A., Ramsdell, A.K., Martin, D., Hu, J., Sawai, E.T.,
and Gutkind, J.S. (2006). The Kaposi’s sarcoma-associated herpes-
virus G protein-coupled receptor as a therapeutic target for the treat-
ment of Kaposi’s sarcoma. Cancer Res. 66, 168–174.
Moore, P.S., Boshoff, C., Weiss, R.A., and Chang, Y. (1996). Molecular
mimicry of human cytokine and cytokine response pathway genes by
kshv. Science 274, 1739–1744.
Moses, A.V., Fish, K.N., Ruhl, R., Smith, P.P., Strussenberg, J.G., Zhu,
L., Chandran, B., and Nelson, J.A. (1999). Long-term infection and
transformation of dermal microvascular endothelial cells by human
herpesvirus 8. J. Virol. 73, 6892–6902.
Muralidhar, S., Pumfery, A.M., Hassani, M., Sadaie, M.R., Azumi, N.,
Kishishita, M., Brady, J.N., Doniger, J., Medveczky, P., and Rosenthal,
L.J. (1998). Identification of kaposin (open reading frame K12) as a hu-
man herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus) trans-
forming gene. J. Virol. 72, 4980–4988.
Nakamura, H., Li, M., Zarycki, J., and Jung, J.U. (2001). Inhibition of
p53 tumor suppressor by viral interferon regulatory factor. J. Virol.
75, 7572–7582.
Naranatt, P.P., Krishnan, H.H., Svojanovsky, S.R., Bloomer, C.,
Mathur, S., and Chandran, B. (2004). Host gene induction and tran-
scriptional reprogramming in Kaposi’s sarcoma-associated herpes-258 Cancer Cell 11, 245–258, March 2007 ª2007 Elsevier Inc.virus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: in-
sights into modulation events early during infection. Cancer Res. 64,
72–84.
Nicholas, J., Ruvolo, V.R., Burns, W.H., Sandford, G., Wan, X.Y., Ciufo,
D., Hendrickson, S.B., Guo, H.G., Hayward, G.S., and Reitz, M.S.
(1997). Kaposis sarcoma-associated human herpesvirus-8 encodes
homologues of macrophage inflammatory protein-1 and interleukin-
6. Nat. Med. 3, 287–292.
Nicolaides, A., Huang, Y.Q., Li, J.J., Zhang, W.G., and Friedman-Kien,
A.E. (1994). Gene amplification and multiple mutations of the K-ras on-
cogene in Kaposi’s sarcoma. Anticancer Res. 14, 921–926.
Pantanowitz, L., and Dezube, B.J. (2004). Advances in the pathobiol-
ogy and treatment of Kaposi sarcoma. Curr. Opin. Oncol. 16, 443–449.
Parsons, C.H., Adang, L.A., Overdevest, J., O’Connor, C.M., Taylor,
J.R., Jr., Camerini, D., and Kedes, D.H. (2006). KSHV targets multiple
leukocyte lineages during long-term productive infection in NOD/SCID
mice. J. Clin. Invest. 116, 1963–1973.
Pillay, P., Chetty, R., and Reddy, R. (1999). Bcl-2 and p53 immunopro-
file in Kaposi’s sarcoma. Pathol. Oncol. Res. 5, 17–20.
Rabkin, C.S., Janz, S., Lash, A., Coleman, A.E., Musaba, E., Liotta, L.,
Biggar, R.J., and Zhuang, Z. (1997). Monoclonal origin of multicentric
Kaposi’s sarcoma lesions. N. Engl. J. Med. 336, 988–993.
Rafii, S., and Lyden, D. (2003). Therapeutic stem and progenitor cell
transplantation for organ vascularization and regeneration. Nat. Med.
9, 702–712.
Safai, B., Johnson, K.G., Myskowski, P.L., Koziner, B., Yang, S.Y.,
Winningham-Ruddles, S., Godbold, J.H., and Dupont, B. (1985). The
natural history of Kaposi’s sarcoma in Acquired Immunodeficiency
Syndrome. Ann. Intern. Med. 103, 744–750.
Sherr, C.J., and DePinho, R.A. (2000). Cellular senescence: mitotic
clock or culture shock? Cell 102, 407–410.
Skobe, M., Brown, L.F., Tognazzi, K., Ganju, R.K., Dezube, B.J., Alitalo,
K., and Detmar, M. (1999). Vascular endothelial growth factor-C
(VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-asso-
ciated Kaposi’s sarcoma. J. Invest. Dermatol. 113, 1047–1053.
Staskus, K.A., Zhong, W., Gebhard, K., Herndier, B., Wang, H., Renne,
R., Beneke, J., Pudney, J., Anderson, D.J., Ganem, D., and Haase, A.T.
(1997). Kaposi’s sarcoma-associated herpesvirus gene expression in
endothelial (spindle) tumor cells. J. Virol. 71, 715–719.
Staudt, M.R., Kanan, Y., Jeong, J.H., Papin, J.F., Hines-Boykin, R.,
and Dittmer, D.P. (2004). The tumor microenvironment controls pri-
mary effusion lymphoma growth in vivo. Cancer Res. 64, 4790–4799.
Wang, H.W., Trotter, M.W., Lagos, D., Bourboulia, D., Henderson, S.,
Makinen, T., Elliman, S., Flanagan, A.M., Alitalo, K., and Boshoff, C.
(2004). Kaposi sarcoma herpesvirus-induced cellular reprogramming
contributes to the lymphatic endothelial gene expression in Kaposi
sarcoma. Nat. Genet. 36, 687–693.
Wang, L., Dittmer, D.P., Tomlinson, C.C., Fakhari, F.D., and Damania,
B. (2006). Immortalization of primary endothelial cells by the K1 protein
of Kaposi’s sarcoma-associated herpesvirus. Cancer Res. 66, 3658–
3666.
Yang, T., Chen, S., Leach, M.W., Manfra, D., Homey, B., Wiekowski,
M., Sullivan, L., Jenh, C., Narula, S., Chensue, S., and Lira, S.A.
(2000). Transgenic expression of the chemokine receptor encoded
by HHV8 induces an angioprolierative disease resembling Kaposi’s
sarcoma. J. Exp. Med. 191, 445–454.
Zhou, F.C., Zhang, Y.J., Deng, J.H., Wang, X.P., Pan, H.Y., Hettler, E.,
and Gao, S.J. (2002). Efficient infection by a recombinant Kaposi’s sar-
coma-associated herpesvirus cloned in a bacterial artificial chromo-
some: application for genetic analysis. J. Virol. 76, 6185–6196.
Accession Numbers
The microarray data can be accessed from NCBI’s Gene Expression
Omnibus (GEO) with accession number GSE6482.
